Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy

The treatment options for PsA have substantially expanded over the last decade. Approximately 40% of patients will not respond to first-line anti-TNF-α therapies. There is limited data to help clinicians select the most appropriate biologic therapy for PsA patients, including guidance for decisions...

Descripción completa

Detalles Bibliográficos
Autores principales: Elliott, Ashley, McGonagle, Dennis, Rooney, Madeleine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709569/
https://www.ncbi.nlm.nih.gov/pubmed/34951926
http://dx.doi.org/10.1093/rheumatology/keab504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709569/
https://www.ncbi.nlm.nih.gov/pubmed/34951926
http://dx.doi.org/10.1093/rheumatology/keab504

Ejemplares similares